Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
South Korea
· Delayed Price · Currency is KRW 14,600
+90 (0.62%)
Apr 29, 2026, 3:30 PM KST
Hyundai Bioscience Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -22,128 | -6,930 | -14,499 | -15,807 | -20,051 | Upgrade
|
| Depreciation & Amortization | 1,306 | 633.82 | 1,435 | 1,782 | 2,703 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 4,769 | - | 7,517 | Upgrade
|
| Loss (Gain) From Sale of Investments | 9.04 | -14.05 | -123.67 | -910.99 | - | Upgrade
|
| Loss (Gain) on Equity Investments | 4,766 | 5,730 | - | -8,834 | -93.91 | Upgrade
|
| Stock-Based Compensation | 22.6 | -77.98 | 402.42 | 596.94 | 578.26 | Upgrade
|
| Provision & Write-off of Bad Debts | 89.74 | 156.13 | -28.78 | 5,260 | -583.99 | Upgrade
|
| Other Operating Activities | 673.67 | 2,717 | 911.44 | -79.49 | 3,925 | Upgrade
|
| Change in Accounts Receivable | -2,170 | 43.52 | 864.23 | 1,184 | 3,526 | Upgrade
|
| Change in Inventory | -161.99 | 1,374 | 358.12 | 403.6 | 864.9 | Upgrade
|
| Change in Accounts Payable | -57.7 | 447.9 | -256.2 | 503.57 | 13.43 | Upgrade
|
| Change in Other Net Operating Assets | 601.48 | -1,824 | 159.77 | -642.06 | 1,063 | Upgrade
|
| Operating Cash Flow | -17,050 | 2,257 | -6,008 | -16,544 | -538.48 | Upgrade
|
| Capital Expenditures | -1,194 | -169.57 | -539.7 | -1,544 | -3,747 | Upgrade
|
| Sale (Purchase) of Intangibles | -19,000 | -2,000 | -47.84 | - | -15.12 | Upgrade
|
| Investment in Securities | -19,836 | -16,934 | 6,000 | 10,210 | -13,010 | Upgrade
|
| Other Investing Activities | 1,233 | -773.14 | -557 | -0.4 | 1,773 | Upgrade
|
| Investing Cash Flow | -38,586 | -19,740 | 5,177 | 8,518 | -12,359 | Upgrade
|
| Long-Term Debt Issued | 14,845 | 20,001 | - | - | - | Upgrade
|
| Total Debt Issued | 14,845 | 20,001 | - | - | - | Upgrade
|
| Short-Term Debt Repaid | -5,000 | -400 | -500 | -500 | - | Upgrade
|
| Long-Term Debt Repaid | -19,386 | -116.58 | -362.88 | -1,194 | -1,246 | Upgrade
|
| Total Debt Repaid | -24,386 | -516.58 | -862.88 | -1,694 | -1,246 | Upgrade
|
| Net Debt Issued (Repaid) | -9,541 | 19,484 | -862.88 | -1,694 | -1,246 | Upgrade
|
| Issuance of Common Stock | 84,258 | 139.96 | 1,094 | 3,596 | 4,449 | Upgrade
|
| Other Financing Activities | -344.38 | -434.78 | -289.18 | -229.04 | -209.66 | Upgrade
|
| Financing Cash Flow | 74,373 | 19,190 | -57.97 | 1,673 | 2,994 | Upgrade
|
| Foreign Exchange Rate Adjustments | -56.06 | 138.47 | -31.72 | -103.42 | -122.29 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | 0 | - | - | - | Upgrade
|
| Net Cash Flow | 18,681 | 1,845 | -920.54 | -6,456 | -10,026 | Upgrade
|
| Free Cash Flow | -18,244 | 2,087 | -6,548 | -18,087 | -4,285 | Upgrade
|
| Free Cash Flow Margin | -518.69% | 13.87% | -69.06% | -230.36% | -46.37% | Upgrade
|
| Free Cash Flow Per Share | -0.17 | 0.16 | -82.31 | -229.72 | -58.04 | Upgrade
|
| Cash Interest Paid | 344.38 | 434.78 | 289.18 | 222.4 | 209.66 | Upgrade
|
| Cash Income Tax Paid | 136.58 | -54.28 | 19.19 | -17.99 | 78.92 | Upgrade
|
| Levered Free Cash Flow | -31,915 | -2,581 | -4,900 | -8,388 | 1,337 | Upgrade
|
| Unlevered Free Cash Flow | -30,393 | -1,135 | -4,704 | -8,108 | 3,214 | Upgrade
|
| Change in Working Capital | -1,788 | 41.17 | 1,126 | 1,449 | 5,467 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.